RT Journal Article
SR Electronic
T1 Comparing microbiological and molecular diagnostic tools for the surveillance of anthrax
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.04.02.24305203
DO 10.1101/2024.04.02.24305203
A1 Ochai, Sunday O.
A1 Hassim, Ayesha
A1 Dekker, Edgar H.
A1 Magome, Thuto
A1 Lekota, Kgaugelo E.
A1 Makgabo, S. Marcus
A1 de Klerk-Loris, Lin-Mari
A1 van Schalkwyk, O. Louis
A1 Kamath, Pauline L.
A1 Turner, Wendy C.
A1 van Heerden, Henriette
YR 2024
UL http://medrxiv.org/content/early/2024/04/03/2024.04.02.24305203.abstract
AB The diagnosis of anthrax, a zoonotic disease caused by Bacillus anthracis can be complicated by detection of closely related species. Conventional diagnosis of anthrax involves microscopy, culture identification of bacterial colonies and molecular detection. Genetic markers used are often virulence gene targets such as Bacillus anthracis protective antigen (pagA, as also called BAPA, occurring on plasmid pXO1), lethal factor (lef, on pXO1), as well as chromosomal (Ba-1) and plasmid (capsule-encoding capB/C, located on pXO2). Combinations of genetic markers using real-time/quantitative polymerase chain reaction (qPCR) are used to confirm B. anthracis from culture but can also be used directly on diagnostic samples to avoid propagation and its associated biorisks and for faster identification. We investigated how the presence of closely related species could complicate anthrax diagnoses with and without culture to standardise the use of genetic markers using qPCR for accurate anthrax diagnosis. Using blood smears from 2012-2020 from wildlife mortalities (n=1708) in Kruger National Park in South Africa where anthrax is endemic, we contrasted anthrax diagnostic results based on qPCR, microscopy, and culture. From smears, 113/1708 grew bacteria in culture, from which 506 isolates were obtained. Of these isolates, only 24.7% (125 isolates) were positive for B. anthracis based on genetic markers or microscopy. However, among these, merely 4/125 (3.2%) were confirmed B. anthracis isolates (based on morphology, microscopy, and sensitivity testing to penicillin and gamma-phage) from the blood smear, likely due to poor survival of spores on stored smears. This study identified B. cereus sensu lato, which included B. cereus and B. anthracis, Peribacillus spp., and Priestia spp. clusters using gyrB gene in selected bacterial isolates positive for BAPA. Using qPCR on blood smears, 52.1% (890 samples) tested positive for B. anthracis based on one or a combination of genetic markers which included the 25 positive controls. Notably, the standard lef primer set displayed the lowest specificity and accuracy. Interestingly, various marker combinations, such as Ba-1+capB, BAPA+capB, Ba-1+BAPA+capB+lef, and BAPA+lef+capB, all demonstrated 100.0% specificity and 98.7% accuracy, while maintaining a sensitivity of 96.6%. The BAPA+lef+Ba-1 combination showed 100% specificity, sensitivity, and accuracy. Using Ba-1+BAPA+lef+capB, as well as Ba-1+BAPA+lef with molecular diagnosis accurately detects B. anthracis in the absence of bacterial culture. Systematically combining microscopy and molecular markers holds promise for notably reducing false positives, thereby significantly enhancing the detection and surveillance of diseases like anthrax in southern Africa and beyond and reducing the need for propagation of the bacteria in culture.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by NSF Grant DEB-2106221 through the NSF-NIH-USDA Ecology and Evolution of Infectious Diseases program to W.C.T, P.L.K and H.V.H.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.Yes